THE ROLE OF IMMUNOTHERAPY IN CANCER TREATMENT: CHECKPOINT INHIBITORS, CAR-T CELLS, AND VACCINES

Area of Science:

• Oncology
• Immunology
• Cancer Therapy

Background:

• Immunotherapy activates the immune system to combat cancer cells, expanding its importance in cancer treatment.
• Checkpoint blockade (CPB) therapy and chimeric antigen receptor (CAR)-modified T cells show significant therapeutic potential.
• Low response rates are often due to suppressed immune responses and lack of tumor-reactive immune infiltration.

Purpose of the Study:

• To explore the combined use of checkpoint inhibitors, CAR T-cells, and vaccines in cancer immunotherapy.
• To investigate strategies for overcoming tumor-induced immunosuppression.
• To identify novel therapeutic targets for enhancing immunotherapy efficacy.

Main Methods:

• Review of current immunotherapy strategies including CPB, CAR T-cells, and dendritic cell (DC) vaccines.
• Analysis of preclinical data on novel immune checkpoint targets.
• Exploration of adjuvant therapies to modify the tumor microenvironment.

Main Results:

• CPB drugs aim to reduce immune suppression, potentially enhancing CAR T-cell and DC vaccine efficacy.
• Despite proven efficacy in specific cancers, current treatments are limited by side effects and tumor immunosuppression.
• Preclinical data suggests targeting immune checkpoints like LAG3, TIM3, CTLA-4, and PD-1 as adjuvant therapies.

Conclusions:

• Combining immunotherapy modalities like CPB, CAR T-cells, and vaccines offers a promising avenue for cancer treatment.
• Modifying the tumor microenvironment through novel checkpoint inhibitors is crucial for improving treatment outcomes.
• Targeting specific immune checkpoints represents a potential strategy to overcome treatment resistance and enhance anti-cancer immunity.